Evidence map›Paper›PMID 40026566›Full record

ReviewThe journal of liquid biopsy2024

Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives.

Molly S C Li, Kevin K S Mok, Landon L Chan, Tony S K Mok

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of liquid biopsy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Molly S C LiDepartment of Clinical Oncology, The Chinese University of Hong Kong, China.
Kevin K S MokDepartment of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China.
Landon L ChanDepartment of Clinical Oncology, The Chinese University of Hong Kong, China.
Tony S K MokDepartment of Clinical Oncology, The Chinese University of Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular profiling is essential for treatment of patients with advanced non-small cell lung cancer. Extensive evidence supports the clinical application of liquid biopsy in molecular profiling and thus has been incorporated into multiple international guidelines. In Asia, clinical practice of liquid biopsy varies between countries owing to difference in molecular characteristics of lung cancer as well as variations in socioeconomic conditions and healthcare systems. The current review covers the landscape and clinical application of liquid biopsy in Asia. An emphasis is placed on epidermal growth factor receptor (

Indexed as

AsiaEpidermal growth factor receptorLiquid biopsyNon-small cell lung cancer

Identifiers

PMID40026566
PMCPMC11863888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.